TICKERNERD
Menu
DOCSDOCSHealthcare · Health Information Services

DOCS Stock Forecast: Doximity, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$35
+6.32% on the day

The 21 Wall Street analysts covering Doximity, Inc. hold a median 12-month price target of $30 — -14.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 4 Nov 2026 — in the upper half. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$5.8B
Ticker Nerd rank
73/ 100
Median analyst target
$30
Analysts covering
21
Revenue$156.6M+7.3% y/y
Operating income$33.6M
Net income$24.3M
Free cash flow$39.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.2%
1M
+24.1%
YTD
−21.7%
1Y
−47.3%
From 52W high
−47.3%
From 52W low
+92.4%
$18
$66
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DOCS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Doximity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
73/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Issuance
89
Accruals
82
Value
72
Revisions
62
Volatility
46
Growth
45
Momentum
27
Size
20

Quality (94): The business earns solid, repeatable profits on what it owns.

Momentum (27): The shares have been drifting down relative to others.

Size (20): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DOCS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DOCS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26DOCSHigh $47Median $30Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
8 Buy11 Hold2 Sell
Low $18Median $30High $47

The green dot is the last close — the median target sits −14.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
29 Sept 2026Evercore ISI GroupMaintainsIn-Line$40 → $35
8 Sept 2026Freedom Capital MarketsDowngradeHold—
8 Sept 2026Freedom Capital MarketsDowngradeHold$24 → $27
21 Aug 2026BarclaysMaintainsEqual-Weight$20 → $27
21 Aug 2026BarclaysMaintainsEqual-Weight—
13 Aug 2026Truist SecuritiesMaintainsHold—
13 Aug 2026Truist SecuritiesMaintainsHold$19 → $24
10 Aug 2026Wells FargoDowngradeUnderweight—
10 Aug 2026Wells FargoDowngradeUnderweight$18
7 Aug 2026Evercore ISI GroupMaintainsIn-Line—
7 Aug 2026Evercore ISI GroupMaintainsIn-Line$22 → $40
7 Aug 2026JP MorganMaintainsNeutral—
7 Aug 2026JP MorganMaintainsNeutral$26 → $31
7 Aug 2026Piper SandlerReiteratesOverweight—
7 Aug 2026Piper SandlerReiteratesOverweight$42 → $47
29 June 2026B of A SecuritiesDowngradeUnderperform—
29 June 2026B of A SecuritiesDowngradeUnderperform$38 → $20
15 May 2026BarclaysDowngradeEqual-Weight—
15 May 2026Goldman SachsMaintainsNeutral—
14 May 2026BairdDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

DOCS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DOCS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Doximity, Inc. returned −47.3% against +14.8% for the S&P 500, dividends included.

DOCS vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26DOCSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DOCS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−5.6%
Analysts raising
1
Analysts cutting
0
Fundamentals

Doximity, Inc. (DOCS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
38.4×

Cheaper than 19% of US stocks

Price / sales
8.9×

Cheaper than 15% of US stocks

Price / book
6.4×

Cheaper than 14% of US stocks

EV / EBITDA
24.9×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
7.3%

Higher than 46% of US stocks

Earnings growth (YoY)
−54.4%

Higher than 10% of US stocks

Gross margin
84.9%

Higher than 94% of US stocks

Operating margin
21.5%

Higher than 81% of US stocks

Net margin
25.5%

Higher than 86% of US stocks

Returns & dividend
Return on equity
17.2%

Higher than 78% of US stocks

Return on assets
10.9%

Higher than 93% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Doximity, Inc. (DOCS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Doximity, Inc. has a market value of $5.8B and an enterprise value of $5.2B.

  • Revenue in the twelve months to 30 June 2026: $655.6M. The latest quarter grew 7.3% year on year.

  • Net income over the same four quarters: $167.0M, a 25.5% net margin.

  • Diluted earnings per share, trailing twelve months: $0.85.

  • Free cash flow in the twelve months to 30 June 2026: $297.0M.

  • Doximity, Inc. spent $400.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 179.8M.

  • Trailing P/E: 38.4×; forward P/E: 20.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Doximity, Inc. employs 880 people — $745K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

DOCS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
DOCSDoximity, Inc.$5.8B73
WAYWaystar Holding Corp.$5.7B40
HTFLHeartFlow, Inc.$4.9B46
HQYHealthEquity, Inc.$9.3B95
HNGEHinge Health, Inc.$9.4B86
BTSGBrightSpring Health Services, Inc.$13.5B93
TEMTempus AI, Inc.$13.5B40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Doximity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DOCS news & analysis

Doximity, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DOCS

PRNewsWire · 5 Nov 2026negative

The DJS Law Group said it is reminding investors of a class action lawsuit against Doximity alleging violations of federal securities laws. The firm encouraged shareholders who purchased DOCS shares during the stated class period to contact it about possible lead plaintiff appointments.

Why it matters — The lawsuit is a legal matter involving Doximity and may be relevant to investors following the company.

DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law

PRNewsWire · 4 Nov 2026negative

Schall, Brown & Schwartz LLP announced a class action lawsuit against Doximity alleging violations of federal securities laws. The firm said investors who purchased DOCS shares during the stated class period may contact it regarding possible lead plaintiff appointments.

Why it matters — The lawsuit and lead plaintiff solicitation are developments DOCS investors may wish to monitor.

DOCS Deadline: DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit

PRNewsWire · 3 Nov 2026negative

Rosen Law Firm reminded investors who purchased Doximity common stock between August 8, 2024, and May 13, 2026, of a November 16, 2026 deadline to seek lead plaintiff status in a securities fraud lawsuit. The firm said eligible purchasers may be entitled to compensation through a contingency-fee arrangement with no out-of-pocket fees or costs.

Why it matters — DOCS investors may wish to note the stated deadline and potential legal proceedings involving the company’s shares.

FAQ

Frequently asked questions about DOCS stock

What is the DOCS stock price forecast for 2026-2027?

The 21 Wall Street analysts covering Doximity, Inc. have a median 12-month price target of $30, with estimates ranging from $18 to $47. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DOCS stock a buy right now?

Of the 21 analysts covering Doximity, Inc., 8 rate it a Buy, 11 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Doximity, Inc. 73 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DOCS?

As at 4 Nov 2026, Doximity, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will DOCS stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies -14.9% from the last close, and Ticker Nerd's factor model ranks Doximity, Inc. 73 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DOCS stock forecast for 2030?

No analyst covering Doximity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DOCS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $47 over the next 12 months.

How has DOCS stock performed over the past year?

Doximity, Inc. returned -47.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Doximity, Inc. do?

Doximity Inc. Class A Common Stock represents ownership in Doximity, a U.S.-based digital platform built for medical professionals.

What is the latest news on DOCS?

The most recent item we track (PRNewsWire, 5 Nov 2026): "Doximity, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DOCS". The DJS Law Group said it is reminding investors of a class action lawsuit against Doximity alleging violations of federal securities laws. The firm encouraged shareholders who purchased DOCS shares during the stated class period to contact it about possible lead plaintiff appointments.

Company

About Doximity, Inc.

Doximity Inc. Class A Common Stock represents ownership in Doximity, a U.S.-based digital platform built for medical professionals. Doximity provides cloud-based tools that help physicians, nurse practitioners, physician assistants, and medical students collaborate with colleagues, coordinate patient care, conduct virtual patient visits, access curated medical news and research, and manage careers and on-call schedules. The company focuses on healthcare communications and workflow software, serving the medical community through features designed for secure networking, telehealth support, and professional productivity. Doximity plays a notable role in the health information services market by connecting clinicians with tools that support day-to-day clinical coordination and access to specialty-specific information.

CEO Mr. Jeffrey A. Tangney · 880 employees · United States · https://www.doximity.com